CTMX

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The Company is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.